Every reporter Jin Zhe Every editor Liang Xiao
Early trading today (May 24)realmoneycasinogamesnodeposit, Kangfang Biotech (HK09926, stock price 34realmoneycasinogamesnodeposit.5 Hong Kong dollars, market value of 298realmoneycasinogamesnodepositHK$..70 million) The stock price fell sharply, falling nearly 45% during the session, and fell 28.2% as of noon, hitting a new low since October 2022. According to market news, the Chinese Phase III clinical data of Kangfang Biotech AK112 in the treatment of EGFR-TKi-treated non-small cell lung cancer fell short of expectations.
Reporter of "Daily Economic News"realmoneycasinogamesnodepositIt is understood that the summary of the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was officially released today. The ASCO official website disclosed a summary of the study data for the above indication AK112 -301, including the main study endpoint progression-free survival (PFS). Analytical data.
In this regard, relevant people from Kangfang Biotech responded exclusively to the reporter of "Business Daily" that the HR corresponding to the progression-free survival (PFS) of AK112 disclosed by ASCO reached 0.46, which is the core data for evaluating clinical study results. The data results are excellent. There is no saying that the data is lower than expected. Currently, the data of AK112 -301 has been accepted as an oral report by the 2024 ASCO Conference due to its excellent results and will be released globally on June 1 according to the organizer's plan.
The reporter also noted that on May 24, AK112 was approved by the State Food and Drug Administration for marketing. It was combined with pemetrexed and carboplatin for the treatment of patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have progressed after treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI).